MARKET

ALNY

ALNY

Alnylam Pharmaceuticals Inc
NASDAQ
312.78
+11.11
+3.68%
After Hours: 314.90 +2.12 +0.68% 19:50 07/02 EDT
OPEN
303.87
PREV CLOSE
301.67
HIGH
317.17
LOW
303.00
VOLUME
1.09M
TURNOVER
--
52 WEEK HIGH
495.55
52 WEEK LOW
273.11
MARKET CAP
41.76B
P/E (TTM)
74.50
1D
5D
1M
3M
1Y
5Y
1D
Wall Street Thinks This Biotech Stock Can Soar 45%. Here's Why Analysts Are Right.
The Motley Fool · 1d ago
July 2026's Top Stocks Estimated To Be Trading Below Their Intrinsic Value
Simply Wall St · 2d ago
How Investors May Respond To Alnylam Pharmaceuticals (ALNY) Expanding Its Enterprise-Wide AI Analytics Partnership
Simply Wall St · 2d ago
Analysts Offer Insights on Healthcare Companies: CG Oncology, Inc. (CGON), Alnylam Pharma (ALNY) and Connect Biopharma Holdings (CNTB)
TipRanks · 3d ago
Alnylam: TTR Growth In Line With Expectations Keeps Risk-Reward Balanced and Price Target Unchanged at $370
TipRanks · 3d ago
Is Alnylam Pharmaceuticals (ALNY) Undervalued Following Its Expanded Komodo Health AI Partnership?
Simply Wall St · 4d ago
Applied Materials To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Monday
Benzinga · 4d ago
Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (ALNY), Biohaven Ltd. (BHVN) and Praxis Precision Medicines (PRAX)
TipRanks · 4d ago
More
About ALNY
Alnylam Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in discovering, developing, manufacturing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). Its marketed products include AMVUTTRA (vutrisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR) in adults ; ONPATTRO (patisiran) for the treatment of the polyneuropathy of hATTR amyloidosis in adults; GIVLAARI (givosiran) for the treatment of adults with acute hepatic porphyria; OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1, and Leqvio (inclisiran), which is being developed and commercialized by its partner, Novartis AG, for the treatment of adults with hypercholesterolemia or mixed dyslipidemia. The Company’s clinical development programs include Cemdisiran, Zilebesiran, Elebsiran, Mivelsiran, ALN-6400, and ALN-HTT02. It is developing Cemdisiran to treat complement-mediated diseases.

Webull offers Alnylam Pharmaceuticals, Inc. stock information, including NASDAQ: ALNY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALNY stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ALNY stock methods without spending real money on the virtual paper trading platform.